We are live on ! Find out more
RG

Redmile Group Portfolio holdings

AUM $1.49B
1-Year Est. Return 208.7%
This Fund
S&P 500
This Quarter Est. Return
+21.28%
1 Year Est. Return
+208.7%
3 Year Est. Return
+777.5%
5 Year Est. Return
+1,114.43%
10 Year Est. Return
+23,630.52%
AUM
$2.03B
AUM Growth
+$384M
Cap. Flow
+$76.6M
Cap. Flow %
3.78%
Top 10 Hldgs %
49.69%
Holding
79
New
15
Increased
27
Reduced
15
Closed
14

Top Buys

Rank Stock Value
1
AZN icon
AstraZeneca
AZN
+$71M
2
SGEN
Seagen Inc. Common Stock
SGEN
+$60.3M
3
ALDR
Alder Biopharmaceuticals
ALDR
+$44.3M
4
NITE
Nightstar Therapeutics plc American Depositary Shares
NITE
+$38.2M
5
INSM icon
Insmed
INSM
+$37.7M

Top Sells

Rank Stock Value
1
JUNO
Juno Therapeutics, Inc.
JUNO
+$66.3M
2
ELV icon
Elevance Health
ELV
+$43.6M
3
AGIO icon
Agios Pharmaceuticals
AGIO
+$35M
4
SYNH
Syneos Health, Inc. Class A Common Stock
SYNH
+$32M
5
PEN icon
Penumbra
PEN
+$31.5M

Sector Composition

Rank Sector Weight
1 Healthcare 94.27%
2 Financials 3.41%
3 Miscellaneous 1.69%
4 Communication Services 0.62%
5 Energy 0.01%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
VRTX icon
26
Vertex Pharmaceuticals
VRTX
$137B
$28.7M 1.42%
189,008
+44,600
+31% +$6.71M
IRTC icon
27
iRhythm Holdings
IRTC
$3.96B
$28.6M 1.41%
552,041
+75,700
+16% +$3.43M
XNCR icon
28
Xencor
XNCR
$1.94B
$27.5M 1.36%
1,200,294
+12,800
+1% +$284K
LJPC
29
DELISTED
La Jolla Pharmaceutical Company
LJPC
$25.2M 1.24%
723,330
+10,050
+1% +$323K
EPZM
30
DELISTED
Epizyme, Inc
EPZM
$23.1M 1.14%
+1,210,000
New +$18.5M
CMRX
31
DELISTED
Chimerix, Inc.
CMRX
$22.2M 1.09%
4,225,575
+18,000
+0.4% +$88.6K
DPLO
32
DELISTED
DIPLOMAT PHARMACY, INC.
DPLO
$19.8M 0.98%
+957,155
New +$16.2M
NVTA
33
DELISTED
Invitae Corporation
NVTA
$19.8M 0.98%
2,112,240
+1,300,000
+160% +$12.3M
BSX icon
34
Boston Scientific
BSX
$67.9B
$17.6M 0.87%
603,493
-491,490
-45% -$13.6M
CBIO
35
Crescent Biopharma
CBIO
$659M
$17M 0.84%
12,141
+6,145
+102% +$7.21M
MEDP icon
36
Medpace
MEDP
$16.8B
$15.9M 0.79%
499,640
+274,600
+122% +$8.39M
AMED
37
DELISTED
Amedisys
AMED
$15.9M 0.78%
283,648
+280,292
+8,352% +$14.8M
JNCE
38
DELISTED
Jounce Therapeutics, Inc. Common Stock
JNCE
$14.9M 0.73%
955,598
-182,772
-16% -$2.58M
SYNH
39
DELISTED
Syneos Health, Inc. Class A Common Stock
SYNH
$14M 0.69%
267,918
-573,500
-68% -$32M
CBAY
40
DELISTED
Cymabay Therapeutics
CBAY
$13.3M 0.65%
+1,647,100
New +$11.1M
LUMO
41
DELISTED
Lumos Pharma, Inc. Common Stock
LUMO
$12.7M 0.63%
+138,744
New +$10.6M
MODN
42
DELISTED
MODEL N, INC.
MODN
$12.5M 0.62%
838,914
-19,400
-2% -$259K
DCPH
43
DELISTED
Deciphera Pharmaceuticals, Inc. Common Stock
DCPH
$12M 0.59%
+722,880
New +$13.2M
ATYR
44
aTyr Pharma
ATYR
$53M
$9.53M 0.47%
+134,771
New +$6.24M
SYRS
45
DELISTED
Syros Pharmaceuticals, Inc. Common Stock
SYRS
$9.44M 0.47%
64,142
-33,184
-34% -$6.24M
CASC
46
DELISTED
Cascadian Therapeutics, Inc.
CASC
$8.06M 0.4%
1,969,969
-1,766,025
-47% -$6.76M
PRQR icon
47
ProQR Therapeutics
PRQR
$323M
$7.77M 0.38%
1,602,975
+6,700
+0.4% +$34.8K
TFX icon
48
Teleflex
TFX
$5.92B
$7.59M 0.37%
+31,365
New +$6.82M
CTMX icon
49
CytomX Therapeutics
CTMX
$699M
$6.95M 0.34%
382,271
-316,121
-45% -$4.93M
PETQ
50
DELISTED
PetIQ, Inc. Class A Common Stock
PETQ
$6.68M 0.33%
+246,743
New +$5.97M
1
2
3 4

Similar funds

FCM
Fairholme Capital Management South Miami, Florida $1.49B AUM 28.35% 1-Year Est. Return
MM
Main Management San Francisco, California $1.49B AUM 22.28% 1-Year Est. Return
WA
WBH Advisory Baltimore, Maryland $1.49B AUM 20.41% 1-Year Est. Return
ACB
Aristotle Capital Boston Boston, Massachusetts $1.49B AUM 32.81% 1-Year Est. Return
LCS
Levin Capital Strategies New York $1.49B AUM 30.44% 1-Year Est. Return
GAM
Gemmer Asset Management Walnut Creek, California $1.49B AUM 42.66% 1-Year Est. Return
MFWP
Mosaic Family Wealth Partners St. Louis, Missouri $1.49B AUM 26.43% 1-Year Est. Return
PMG
ProVise Management Group Clearwater, Florida $1.49B AUM 21.79% 1-Year Est. Return

Redmile Group's Q3 2017 Portfolio in Review

As of Q3 2017, Redmile Group held 79 positions worth $2.03B, up 23% from $1.64B the previous quarter. Its ten largest holdings account for 50% of the portfolio.

Redmile Group deployed $76.6M of net new capital in Q3 2017, opening 15 new positions and adding to 27 existing holdings. Its largest new stake was AstraZeneca: 1,123,150 shares worth $76.1M.

By sector, the portfolio is most concentrated in Healthcare at 94% of assets, down from 95% a quarter earlier, followed by Financials and Miscellaneous.

On the sell side, the largest reduction was Syneos Health, Inc. Class A Common Stock, an estimated $32M trimmed.

  • Redmile Group's largest Q3 2017 buy was AstraZeneca: 1,123,150 shares worth $76.1M.
  • Redmile Group added most to Seagen Inc. Common Stock in Q3 2017, an estimated $60.3M increase.
  • Redmile Group's biggest Q3 2017 reduction was Syneos Health, Inc. Class A Common Stock, cutting an estimated $32M.
  • Redmile Group fully exited Juno Therapeutics, Inc. in Q3 2017, selling an estimated $66.3M.
  • Redmile Group's ten largest holdings make up 50% of its $2.03B portfolio in Q3 2017.
  • Redmile Group opened 15 new positions and closed 14 in Q3 2017.
  • Redmile Group's portfolio value rose 23% quarter-over-quarter to $2.03B.

Based on Redmile Group's 13F filing for Q3 2017, filed 14 Nov 2017.